Efficacy of Tocilizumab for Refractory Sensitized Patients Awaiting Heart Transplantation

Deen, J.; Patel, J.; Kittleson, M.; Chang, D.; Singer-Englar, T.; Patel, N.; Nikolova, Andriana P.; Ramzy, Danny; Czer, L.; Kobashigawa, J.A.

doi:10.1016/j.healun.2022.01.1402

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL‐6 inhibition has also been evaluated clinically as a component of desensitization therapy with promising initial results 71,72 . In one study, tocilizumab was incorporated into a perioperative desensitization protocol for heart transplant recipients with a positive virtual crossmatch 72 .…”

Section: Il‐6 Blockade In Heart Transplantationmentioning

confidence: 99%

“…Based on experimental and pre-clinical evidence supporting the use of IL-6 signaling blockade to prevent heart allograft rejection, IL-6 inhibition has also been evaluated clinically as a component of desensitization therapy with promising initial results. 71,72 In one study, tocilizumab was incorporated into a perioperative desensitization protocol for heart transplant recipients with a positive virtual crossmatch. 72…”

Section: Clinical Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Targeting IL-6 to prevent cardiac allograft rejection

Miller

Madsen

2022

American Journal of Transplantation

View full text Add to dashboard Cite

Section: Il‐6 Blockade In Heart Transplantationmentioning

confidence: 99%

Section: Clinical Applicationsmentioning

confidence: 99%

Targeting IL-6 to prevent cardiac allograft rejection

Miller

Madsen

2022

American Journal of Transplantation

View full text Add to dashboard Cite

Current Strategies in Immune Modulation and Desensitization Protocols

Patel,

Coutance

2023

Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease

View full text Add to dashboard Cite

Cardiac Allograft Rejection: Strategies for Success in the Face of Immune Challenges

Patail,

Khan,

Aggarwal-Gupta

et al. 2023

Cardiology in Review

View full text Add to dashboard Cite

Heart transplantation for patients with end-stage heart failure refractory to medical therapy has remained definitive treatment with significant advances in posttransplant care. Despite improvement in postoperative morbidity and mortality, acute cellular rejection (ACR) and antibody-mediated rejection (AMR) remain substantial challenges that can lead to allograft failure and patient mortality. Immunosuppressive agents have been the mainstay of both prevention and treatment for ACR and AMR; however, many challenges exist with traditional therapies. There are a multitude of molecular pathways involved in mediating the humoral and cellular response to rejection, offering various targets for treatment. This review summarizes therapies used in the management of ACR and AMR as extrapolated from use in induction therapy and treatment of other solid-organ transplant rejection. Future studies focused on cardiac transplant recipients are needed to expand therapeutic options.

show abstract

Efficacy of Tocilizumab for Refractory Sensitized Patients Awaiting Heart Transplantation

Cited by 3 publications

References 0 publications

Targeting IL-6 to prevent cardiac allograft rejection

Targeting IL-6 to prevent cardiac allograft rejection

Current Strategies in Immune Modulation and Desensitization Protocols

Cardiac Allograft Rejection: Strategies for Success in the Face of Immune Challenges

Contact Info

Product

Resources

About